{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:01:15Z","timestamp":1783008075025,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jcjo.2021.09.008","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T12:23:41Z","timestamp":1634819021000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Subfoveal choroidal thickness as a potential predictor of treatment response after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1218-1270","authenticated-orcid":false,"given":"Maria","family":"Jim\u00e9nez-Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Saenz-Franc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Calvo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 I.","family":"Fern\u00e1ndez-Vigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9944-6736","authenticated-orcid":false,"given":"Juan","family":"Donate-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8573-2555","authenticated-orcid":false,"given":"Lorenzo","family":"L\u00f3pez-Guajardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2021.09.008_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"10","author":"Yannuzzi","year":"1990","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/ICU.0b013e3282fb7c33","article-title":"Polypoidal choroidal vasculopathy and treatments","volume":"19","author":"Gomi","year":"2008","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0003","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ceo.13114","article-title":"Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of \u201cexpanded spectra\u201d\u2014a review","volume":"46","author":"Dansingani","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0004","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.oret.2019.08.002","article-title":"The pachychoroid disease spectrum\u2014and the need for a uniform classification system","volume":"3","author":"Siedlecki","year":"2019","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0005","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1097\/IAE.0000000000001872","article-title":"Prevalence of polypoidal choroidal vasculopathy in white patients with exudative age-related macular degeneration: systematic review and meta-analysis","volume":"38","author":"Lorentzen","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0006","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.oret.2019.04.018","article-title":"Anti\u2013vascular endothelial growth factor resistance in exudative macular degeneration and polypoidal choroidal vasculopathy","volume":"3","author":"Kokame","year":"2019","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0007","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jcjo.2019.10.011","article-title":"Polypoidal choroidal vasculopathy in Canada","volume":"55","author":"Lam","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0008","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/jcm4050782","article-title":"Polypoidal choroidal vasculopathy in Asians","volume":"4","author":"Wong","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0009","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0010","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study, a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0011","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"Cheung","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0013","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/IAE.0000000000002583","article-title":"Difference between pachychoroid and nonpachychoroid polypoidal choroidal vasculopathy and their response to anti\u2013vascular endothelial growth factor therapy","volume":"40","author":"Chang","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0014","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2008.05.032","article-title":"Enhanced depth imaging spectral-domain optical coherence tomography","volume":"146","author":"Spaide","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0016","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0161-6420(13)38009-9","article-title":"Early treatment diabetic retinopathy study design and baseline patient characteristics: ETDRS report number 7","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0017","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ophtha.2012.05.027","article-title":"The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1)","volume":"119","author":"Chew","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0018","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00417-020-04620-z","article-title":"Analysis of choroidal thickness and vascularity in patients with unilateral polypoidal choroidal vasculopathy","volume":"258","author":"Lee","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0184058","article-title":"Comparison of clinical features and 3-month treatment response among three different choroidal thickness groups in polypoidal choroidal vasculopathy","volume":"12","author":"Kong","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0020","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s004170000180","article-title":"Polypoidal choroidal vasculopathy in Caucasians","volume":"238","author":"Lafaut","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0021","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1167\/iovs.14-16236","article-title":"Toward a specific classification of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degeneration","volume":"56","author":"Coscas","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0022","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00417-020-04844-z","article-title":"The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification","volume":"259","author":"van Dijk","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000515295","article-title":"Polypoidal choroidal vasculopathy in Caucasians morphological findings from multimodal retinal imaging","volume":"244","author":"Sim\u00e3o","year":"2021","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0024","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1097\/IAE.0000000000001346","article-title":"Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness","volume":"36","author":"Lee","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0025","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00417-015-3221-x","article-title":"Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy","volume":"254","author":"Kim","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0026","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","article-title":"Polypoidal choroidal vasculopathy","volume":"49","author":"Ciardella","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0027","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/aos.13646","article-title":"Presenting characteristics and prevalence of polypoidal choroidal vasculopathy in Scandinavian patients with treatment-naive exudative age-related macular degeneration","volume":"96","author":"Dam Lorentzen","year":"2018","journal-title":"Acta Ophtalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0028","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jfma.2019.04.012","article-title":"Management of polypoidal choroidal vasculopathy: experts consensus in Taiwan","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2009.02.012","article-title":"Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy","volume":"148","author":"Cho","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000503834","article-title":"Clinical characteristics of polypoidal choroidal vasculopathy and anti-vascular endothelial growth factor treatment response in caucasians","volume":"243","author":"Kokame","year":"2020","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0031","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/bjophthalmol-2013-303444","article-title":"Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response","volume":"98","author":"Hatz","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0032","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12886-016-0305-2","article-title":"Prospective clinical trial of intravitreal aflibercept treatment for polypoidal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results","volume":"16","author":"Kokame","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0033","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1111\/aos.12110","article-title":"Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types","volume":"91","author":"Kawamura","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0034","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/bjophthalmol-2016-309264","article-title":"Comparison of OCT angiography and indocyanine green angiographic findings with subtypes of polypoidal choroidal vasculopathy","volume":"101","author":"Tanaka","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0035","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ajo.2014.01.019","article-title":"Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration","volume":"157","author":"Kang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0036","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/IAE.0000000000000654","article-title":"Choroidal thickness in relation to ethnicity measured using enhanced depth imaging optical coherence tomography","volume":"36","author":"Karapetyan","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/genes11111335","article-title":"Genetic variants affecting anti-vegf drug response in polypoidal choroidal vasculopathy patients: a systematic review and meta-analysis","volume":"11","author":"D\u00edaz-Villamar\u00edn","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0038","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/01.APO.0000656976.47696.7d","article-title":"Genetic association of age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"9","author":"Chen","year":"2020","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.09.008_bib0039","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1442-9071.2004.00827.x","article-title":"Pathological features of surgically excised polypoidal choroidal vasculopathy membranes","volume":"32","author":"Kuroiwa","year":"2004","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418221003586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418221003586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:11:24Z","timestamp":1757794284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418221003586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0008418221003586"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2021.09.008","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subfoveal choroidal thickness as a potential predictor of treatment response after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2021.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}